Driehaus Capital SKYE Position
ExitedDriehaus Capital exited their position in Skye Bioscience, Inc. (SKYE) in Q4 2025, after holding the stock for 7 quarters.
The position was first reported in Q2 2024 and has been tracked across 7 quarterly 13F filings.
2 other tracked funds also hold SKYE.
There is an upcoming Phase 2 readout for Nimacimab injection in 218 days (Nov 20, 2026), making the timing of Driehaus's position particularly relevant.
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Full company profile →Short Interest
6.8%
1.4 days to cover
Driehaus Capital SKYE Position History
Frequently Asked Questions
Does Driehaus Capital own SKYE?
No. Driehaus Capital exited their position in Skye Bioscience, Inc. (SKYE) in Q4 2025. They previously held the stock for 7 quarters.
How many hedge funds own SKYE?
2 specialist biotech hedge funds currently hold SKYE, including Baker Bros. Advisors, Perceptive Advisors. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy SKYE?
Driehaus Capital's position in SKYE was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's SKYE position increasing or decreasing?
Driehaus Capital completely exited their SKYE position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
SKYECompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →